Moreover, analysis of ctDNA in the blood samples of 77.3% of HCC patients undergoing anti-PD-1 therapy revealed the presence of >1 genetic alterations, with TP53 being the most common mutated gene, observed in 11 patients [35]. This evidence concerns the gene TP53 and hepatocellular carcinoma.